27374484|t|Plasmablastic transformation of plasma cell myeloma with heterotropic expression of CD3 and CD4: a case report
27374484|a|Plasmablastic lymphoma (PBL) can rarely be seen as a transformation from plasma cell myeloma (PCM), especially in late stages of the disease where it portends a poorer prognosis and a different line of management for the patient. When unrelated to PCM, PBL is considered to be a separate aggressive variant of B-cell lymphoma typically seen in the oral cavity of immunocompromised adults. We describe a case of plasmablastic transformation having a pan T-cell phenotype with CD3 and CD4 positivity, in an immunocompetent elderly lady diagnosed with PCM. This 60- year - old lady presented with worsening backache and a 2-cm skin nodule in the left cervical region, while she was on treatment with vincristine, cyclophosphamide, dexamethasone (VCD), and bortezomib. On biopsy, the skin nodule showed an infiltrating lymphoid tumor composed of immunoblastic cells with brisk mitosis and apoptosis. On Immunohistochemistry (IHC), lymphoid cells revealed plasma cell markers CD38, CD138, CD56, and MUM1. Pan-T-cell markers CD3 and CD4 were also diffusely expressed in tumor cells. B-cell markers CD20 and PAX5 were not expressed; c-Myc IHC and EBER by in situ hybridization (ISH) were negative in the tumor. Mitotic index by Ki67 was >95%. Thus, a diagnosis of plasmablastic transformation in a known PCM case was made. This is the first case, to the best of our knowledge, with a heterotropic T-cell phenotype in a plasmablastic transformation from PCM. It is critical to correctly diagnose such cases as they may occasionally be misinterpreted as T-cell neoplasms. Clinically, a more aggressive treatment is indicated for such patients. Further studies in these cases may enhance our understanding of complex underpinnings of lymphoma biology.
27374484	0	28	Plasmablastic transformation	T043	C0040682
27374484	32	51	plasma cell myeloma	T191	C0026764
27374484	57	80	heterotropic expression	T045	C1171362
27374484	84	87	CD3	T116,T129	C0108779
27374484	92	95	CD4	T116,T129,T192	C0003323
27374484	99	110	case report	T170	C0007320
27374484	111	133	Plasmablastic lymphoma	T191	C3472614
27374484	135	138	PBL	T191	C3472614
27374484	164	178	transformation	T043	C0040682
27374484	184	203	plasma cell myeloma	T191	C1532559
27374484	205	208	PCM	T191	C1532559
27374484	225	236	late stages	T079	C1279941
27374484	244	251	disease	T047	C0012634
27374484	272	288	poorer prognosis	T033	C0278252
27374484	313	323	management	T058	C0376636
27374484	332	339	patient	T101	C0030705
27374484	359	362	PCM	T191	C0026764
27374484	364	367	PBL	T191	C3472614
27374484	399	417	aggressive variant	T080	C0205419
27374484	421	436	B-cell lymphoma	T191	C0079731
27374484	459	470	oral cavity	T030	C0226896
27374484	474	491	immunocompromised	T033	C0085393
27374484	492	498	adults	T100	C0001675
27374484	522	550	plasmablastic transformation	T043	C0040682
27374484	560	580	pan T-cell phenotype	T116,T129	C0108779
27374484	586	589	CD3	T116,T129	C0108779
27374484	594	597	CD4	T116,T129,T192	C0003323
27374484	616	631	immunocompetent	T201	C1512656
27374484	632	644	elderly lady	T100	C0524338
27374484	645	654	diagnosed	T033	C0011900
27374484	660	663	PCM	T191	C1532559
27374484	674	678	year	T079	C0439234
27374484	681	689	old lady	T100	C0524338
27374484	705	714	worsening	T033	C1457868
27374484	715	723	backache	T184	C0004604
27374484	735	746	skin nodule	T020	C0037287
27374484	754	774	left cervical region	T029	C0556956
27374484	793	802	treatment	T061	C0087111
27374484	808	819	vincristine	T109,T121	C0042679
27374484	821	837	cyclophosphamide	T109,T121	C0010583
27374484	839	852	dexamethasone	T109,T121	C0011777
27374484	854	857	VCD	T109,T121	C0011777
27374484	864	874	bortezomib	T109,T121	C1176309
27374484	879	885	biopsy	T060	C0005558
27374484	891	902	skin nodule	T020	C0037287
27374484	913	925	infiltrating	T046	C0332448
27374484	926	940	lymphoid tumor	T191	C0598798
27374484	953	972	immunoblastic cells	T025	C0024264
27374484	984	991	mitosis	T043	C0026255
27374484	996	1005	apoptosis	T043	C0162638
27374484	1010	1030	Immunohistochemistry	T060	C0021044
27374484	1032	1035	IHC	T060	C0021044
27374484	1038	1052	lymphoid cells	T025	C0086574
27374484	1062	1073	plasma cell	T025	C0032112
27374484	1074	1081	markers	T201	C0005516
27374484	1082	1086	CD38	T116	C0075742
27374484	1088	1093	CD138	T116,T123	C1609943
27374484	1095	1099	CD56	T116,T129	C0108754
27374484	1105	1109	MUM1	T116,T123	C0299544
27374484	1111	1129	Pan-T-cell markers	T116,T129	C0108779
27374484	1130	1133	CD3	T116,T129	C0108779
27374484	1138	1141	CD4	T116,T129,T192	C0003323
27374484	1152	1171	diffusely expressed	T045	C1171362
27374484	1175	1186	tumor cells	T025	C0597032
27374484	1188	1202	B-cell markers	T129	C0443980
27374484	1203	1207	CD20	T116,T129	C0054946
27374484	1212	1216	PAX5	T116,T123	C0167636
27374484	1237	1242	c-Myc	T028	C0079068
27374484	1243	1246	IHC	T060	C0021044
27374484	1251	1255	EBER	T116,T123	C0033684
27374484	1259	1280	in situ hybridization	T063	C0162788
27374484	1282	1285	ISH	T063	C0162788
27374484	1292	1300	negative	T033	C1513916
27374484	1308	1313	tumor	T191	C0027651
27374484	1315	1328	Mitotic index	T034	C0812425
27374484	1332	1336	Ki67	T059	C4049944
27374484	1355	1364	diagnosis	T033	C0011900
27374484	1368	1396	plasmablastic transformation	T043	C0040682
27374484	1408	1411	PCM	T191	C1532559
27374484	1488	1517	heterotropic T-cell phenotype	T130	C2826610
27374484	1523	1551	plasmablastic transformation	T043	C0040682
27374484	1557	1560	PCM	T191	C0026764
27374484	1590	1598	diagnose	T033	C0011900
27374484	1656	1662	T-cell	T025	C0039194
27374484	1663	1672	neoplasms	T191	C0027651
27374484	1674	1684	Clinically	T080	C0205210
27374484	1693	1713	aggressive treatment	T061	C0087111
27374484	1736	1744	patients	T101	C0030705
27374484	1754	1761	studies	T062	C2603343
27374484	1771	1776	cases	T169	C0868928
27374484	1781	1788	enhance	T169	C0442805
27374484	1810	1817	complex	T080	C0439855
27374484	1818	1831	underpinnings	T204	C1031756
27374484	1835	1843	lymphoma	T191	C0024299
27374484	1844	1851	biology	T091	C0005532